{"disease":{"id":"monoclonal-gammopathy-of-uncertain-significance","name":"monoclonal gammopathy of uncertain significance"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06987708","title":"Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":67,"lead_sponsor_name":"Hackensack Meridian Health","has_results":false},{"nct_id":"NCT05939037","title":"Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"UMC Utrecht","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}